37691654|t|4-phenylbutyric acid re-trafficking hERG/G572R channel protein by modulating the endoplasmic reticulum stress-associated chaperones and endoplasmic reticulum-associated degradation gene.
37691654|a|Background: Long QT syndrome type 2 (LQT2) is caused by mutations in the KCNH2/human ether-a-go-go-related gene (hERG). Some hERG genetic mutation-associated diseases are alleviated by hERG-specific drug chaperones (glycerol, dimethyl sulfoxide, trimethylamine N-oxide, thapsigargin), delayed rectifier K+ current (IKr) blockers methanesulfonanilide E4031, the antihistamine astemizole, or the prokinetic drug cisapride, and the anti-arrhythmic drug quinidine. Meanwhile, many in vivo and in vitro studies have reported the efficacy of 4-phenylbutyric acid (4-PBA) in diseases with inherited genetic mutations. This study aims to explore potential therapeutic agents for hERG/G572R mutated ion channel. Methods: pcDNA3/hERG [wild type (WT)]-FLAG and pcDNA3/hERG (G572R)-FLAG plasmids were transfected into HEK293 cells. A western blot (WB) experiment was conducted to analyze protein expression. Quantitative real-time polymerase chain reaction (qPCR) was used to analyze the messenger RNA (mRNA) expression levels in the WT/G572R heterozygous HEK293 cell model treated with or without 4-PBA. The interaction between WT/G572R and BIP (GRP78), GRP94, and 3-hydroxy-3-methylglutaryl coenzyme A reductase degradation protein 1 (HRD1) was tested by co-immunoprecipitation (co-IP). To investigate the effect of 4-PBA on the WT/G572R channel current, we used electrophysiological assays (patch-clamp electrophysiological recordings). Results: The results showed that WT/G572R activated the ATF6 pathway in the endoplasmic reticulum stress (ERS), the ERS response markers GRP78, GRP94, and calreticulin (CRT)/calnexin (CNX), and HRD1, which decreased after application of the ERS inhibitor 4-PBA. The results of co-IP confirmed that the ability of hERG interacted with GRP78, GRP94, and HRD1. Moreover, 4-PBA increased the current of WT/G572R and reversed the gating kinetics of the WT/G572R channel. Conclusions: 4-PBA corrects hERG channel transport defects by inhibiting excessive ERS and the endoplasmic reticulum-associated degradation (ERAD)-related gene E3 ubiquitin ligase HRD1. Additionally, 4-PBA improved WT/G572R channel current. 4-PBA is expected to be developed as a new treatment method for LQT2.
37691654	0	20	4-phenylbutyric acid	Chemical	MESH:C075773
37691654	36	40	hERG	Gene	3757
37691654	41	46	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	199	222	Long QT syndrome type 2	Disease	MESH:D008133
37691654	224	228	LQT2	Disease	MESH:D008133
37691654	260	265	KCNH2	Gene	3757
37691654	272	298	ether-a-go-go-related gene	Gene	2078
37691654	300	304	hERG	Gene	3757
37691654	312	316	hERG	Gene	3757
37691654	372	376	hERG	Gene	3757
37691654	403	411	glycerol	Chemical	MESH:D005990
37691654	413	431	dimethyl sulfoxide	Chemical	MESH:D004121
37691654	433	455	trimethylamine N-oxide	Chemical	MESH:C005855
37691654	457	469	thapsigargin	Chemical	MESH:D019284
37691654	516	542	methanesulfonanilide E4031	Chemical	-
37691654	562	572	astemizole	Chemical	MESH:D016589
37691654	597	606	cisapride	Chemical	MESH:D020117
37691654	621	631	arrhythmic	Disease	OMIM:212500
37691654	637	646	quinidine	Chemical	MESH:D011802
37691654	723	743	4-phenylbutyric acid	Chemical	MESH:C075773
37691654	745	750	4-PBA	Chemical	MESH:C075773
37691654	858	862	hERG	Gene	3757
37691654	863	868	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	906	910	hERG	Gene	3757
37691654	944	948	hERG	Gene	3757
37691654	950	955	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	993	999	HEK293	CellLine	CVCL:0045
37691654	1212	1217	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	1231	1237	HEK293	CellLine	CVCL:0045
37691654	1273	1278	4-PBA	Chemical	MESH:C075773
37691654	1307	1312	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	1317	1320	BIP	Gene	3309
37691654	1322	1327	GRP78	Gene	3309
37691654	1330	1335	GRP94	Gene	7184
37691654	1412	1416	HRD1	Gene	84447
37691654	1493	1498	4-PBA	Chemical	MESH:C075773
37691654	1509	1514	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	1651	1656	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	1671	1675	ATF6	Gene	22926
37691654	1752	1757	GRP78	Gene	3309
37691654	1759	1764	GRP94	Gene	7184
37691654	1770	1782	calreticulin	Gene	811
37691654	1784	1787	CRT	Gene	811
37691654	1789	1797	calnexin	Gene	821
37691654	1799	1802	CNX	Gene	821
37691654	1809	1813	HRD1	Gene	84447
37691654	1870	1875	4-PBA	Chemical	MESH:C075773
37691654	1928	1932	hERG	Gene	3757
37691654	1949	1954	GRP78	Gene	3309
37691654	1956	1961	GRP94	Gene	7184
37691654	1967	1971	HRD1	Gene	84447
37691654	1983	1988	4-PBA	Chemical	MESH:C075773
37691654	2017	2022	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	2066	2071	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	2094	2099	4-PBA	Chemical	MESH:C075773
37691654	2109	2113	hERG	Gene	3757
37691654	2241	2260	E3 ubiquitin ligase	Gene	158506
37691654	2261	2265	HRD1	Gene	84447
37691654	2281	2286	4-PBA	Chemical	MESH:C075773
37691654	2299	2304	G572R	ProteinMutation	tmVar:p|SUB|G|572|R;HGVS:p.G572R;VariantGroup:0;CorrespondingGene:3757;RS#:9333649;CorrespondingSpecies:9606;CA#:5249
37691654	2322	2327	4-PBA	Chemical	MESH:C075773
37691654	2386	2390	LQT2	Disease	MESH:D008133
37691654	Association	MESH:C005855	3757
37691654	Association	MESH:C075773	RS#:9333649;HGVS:p.G572R;CorrespondingGene:3757
37691654	Positive_Correlation	MESH:D008133	RS#:9333649;HGVS:p.G572R;CorrespondingGene:3757
37691654	Association	MESH:D008133	3757
37691654	Association	MESH:D008133	2078
37691654	Negative_Correlation	MESH:D016589	3757
37691654	Negative_Correlation	MESH:C075773	MESH:D008133
37691654	Association	MESH:D004121	3757
37691654	Association	MESH:D019284	3757
37691654	Association	MESH:D005990	3757
37691654	Association	158506	3757
37691654	Negative_Correlation	MESH:D020117	3757
37691654	Negative_Correlation	MESH:D011802	OMIM:212500
37691654	Negative_Correlation	MESH:D011802	3757
37691654	Association	OMIM:212500	3757
37691654	Association	MESH:C075773	3757

